UK flag Brexit: What We Are (And Aren't) Doing Get the Fool's analysis on what the UK leaving the EU means for investors

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.


Updates from The Motley Fool

Latest updates on Alnylam Pharmaceuticals from Fool.com.


Stock Performance

ALNY vs. S&P 500 | 2 Year Performance
View Interactive ALNY Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alnylam Pharmaceuticals.
Current Price: $54.31
Prev Close: $56.95
Open: $54.00
Bid: $54.00
Ask: $55.80
Day's Range: $53.00 - $55.54
52wk Range: $49.96 - $140.00
Volume: 1,812,647
Avg Vol 1,005,274
Market Cap: $4.60B
P/E (ttm): -14.10
EPS (ttm): -$4.04
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alnylam Pharmaceuticals.
CAPS Rating 3 out of 5
 
379 Outperform
42 Underperform
CAPS All Stars
 
79 Outperform
18 Underperform

How do you think Alnylam Pharmaceuticals will perform against the market?



You pick for Alnylam Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John M. Maraganore, CEO

83% Approve

Based on 11 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alnylam Pharmaceuticals.

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers